Filing Details

Accession Number:
0000899243-23-009182
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-20 20:31:01
Reporting Period:
2023-03-16
Accepted Time:
2023-03-20 20:31:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1658551 Amylyx Pharmaceuticals Inc. AMLX Pharmaceutical Preparations (2834) 464600503
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1898314 B. Justin Klee C/O Amylyx Pharmaceuticals, Inc.
43 Thorndike Street
Cambridge MA 02141
Co-Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-16 96,555 $31.84 2,796,062 No 4 S Direct
Common Stock Disposition 2023-03-16 3,445 $32.48 2,792,617 No 4 S Direct
Common Stock Acquisiton 2023-03-16 50,000 $0.00 2,842,617 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2023-03-16 225,000 $0.00 225,000 $32.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
225,000 2033-03-16 No 4 A Direct
Footnotes
  1. These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.32 to $32.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  4. The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
  5. 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.